Carboplatin in Combination with Epirubicin and Cyclophosphamide in Patients with Advanced Ovarian Cancer: A phase II study

References

• Högberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population‐based material of ovarian carcinomas. Gynecol Oncol 1993; 48: 38–49
   PubMedGoogle Scholar
• Sutton G P, Stehman F B, Einhorn L H, Roth L M, Blessing J A, Ehrlich C E. Ten‐year follow‐up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989; 7: 223–9
   PubMed Web of Science ®Google Scholar
• Omura G, Blessing J A, Ehrlich C E, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 1986; 57: 1725–30
   PubMed Web of Science ®Google Scholar
• Belinson J L, McClure M, Ashikaga T, Krakoff I H. Treatment of advanced and recurrent ovarian carcinoma with cyclophosphamide, doxorubicin, and cisplatin. Cancer 1984; 54: 1983–90
   PubMedGoogle Scholar
• Taylor A E, Wiltshaw E, Gore M E, Fryatt I, Fisher C. Longterm follow‐up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994; 12: 2066–70
   PubMed Web of Science ®Google Scholar
• Launchbury A P, Habboubi N. Controversy. Epirubicin and doxorubicin: a comparison of their characteristics. therapeutic activity and toxicity. Cancer Treat Rev 1993; 19: 197–228
   PubMed Web of Science ®Google Scholar
• Nejt J P, ten Bokkel Huinik W W, van der Burg M E L, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP‐5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157–68
   PubMedGoogle Scholar
• Bertelsen K, Jakobsen A, Andersen J E, et al. A randomized study of cyclophosphamide and cis‐platin with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9
   PubMed Web of Science ®Google Scholar
• Omura G A, Bundy B N, Berek J S, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457–65
   PubMed Web of Science ®Google Scholar
• GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia) Italy. Long‐term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115–7
   PubMedGoogle Scholar
• Conte P F, Bruzzone M, Carnino F, et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: A randomized trial in stage III‐IV epithelian ovarian carcinoma. J Clin Oncol 1991; 9: 658–63
   PubMed Web of Science ®Google Scholar
• Alberts D S, Green S, Hannigan E V, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10: 706–17
   PubMed Web of Science ®Google Scholar
• Adams M, Kerby I J, Rocker I, Evans A, Johansen K, Franks C R, on behalf of the Swons Gynaecological Cancer Group. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 1989; 28: 57–60
   PubMed Web of Science ®Google Scholar
• Mangioni C, Bolis G, Pecorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J. Natl Cancer Inst 1989; 81: 1464–71
   PubMedGoogle Scholar
• Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin‐cyclophos‐phamide versus carboplatin‐cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin Oncol 1992; 10: 718–26
   Google Scholar
• ten Bokkel Huinik W W, Dalesio O, Rodenshuis S, et al. Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: Long‐term treatment results of a study of the Gynecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute. Semin Oncol 1992; 19(Suppl 2)99–101
   PubMedGoogle Scholar
• Edmonson J H, McCormack G M, Wieand H S, et al. Cyclophosphamide‐cisplatin versus cyclophosphamide‐carbo‐platin in stage III‐IV ovarian carcinoma: A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989; 81: 1500–4
   PubMedGoogle Scholar
• Belpomme D, Bugat R, Rives M, et al. Carboplatin versus cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III‐IV ovarian carcinoma: Result of an Artac phase III trial. Proc ASCO 1992; 11: 227
   Google Scholar
• Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 1991; 303: 884–93
   PubMedGoogle Scholar
• Vermorken J B, ten Bokkel Huinik W W, Eisenhauer E A, et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4(Suppl 4)S41–S48
   PubMedGoogle Scholar
• Mouridsen H T. New cytotoxic drugs in treatment of breast cancer. Acta Oncol 1990; 29: 343–7
   PubMed Web of Science ®Google Scholar
• Homesley H D, Harry D S, O'Toole R V, et al. Randomized comparision of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. Am J Clin Oncol (CCT) 1992; 15: 129–34
   PubMedGoogle Scholar
• Bezwoda W R. Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4–epi‐adriamycin in combination with cisplatin and cyclophosphamide. Med Pediatr Oncol 1986; 14: 26–9
   PubMedGoogle Scholar
• Hernádi Z, Juhász B, Póka R, Lampé L G. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4–epi‐doxorubicin in the treatment of advanced ovarian cancer. Int J Gynecol Obstet 1988; 27: 199–204
   PubMed Web of Science ®Google Scholar
• Tomirotti M, Perrone S, Giè P, et al. Cisplatin (P) versus cyclophosphamide, Adriamycin and cisplatin (CAP) for stage III‐IV epithelial ovarian carcinoma: A prospective randomized trial. Tumori 1988; 74: 573–7
   PubMedGoogle Scholar
• The Ovarian Cancer Meta‐Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A metaanalysis. J Clin Oncol 1991; 9: 1668–74
   PubMedGoogle Scholar
• Bertelsen K, Kern Hansen M, Hjortkaer Pederson P, et al. The prognostic and therapeutic value of second‐look laparotomy in advanced ovarian cancer. Br J Obstet Gynaecol 1988; 95: 1231–6
   PubMedGoogle Scholar
• Calvert A H, Newell D R, Gumbrell L A, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56
   PubMed Web of Science ®Google Scholar